Patent · US Active

Crystalline forms of a factor XIa inhibitor

US9920034B2 · kind B2 · utility

0Cited by

4References

19Claims

0Family size

Assignee

Bristol-Myers Squibb Company · US

Inventors

Marta Dabros · Foster City, US
Chenkou Wei · Princeton Junction, US

Key dates

Filing date	Oct 11, 2013
Grant date	Mar 20, 2018
Priority date	—
Expiry date	Oct 11, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/13
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The instant invention provides crystalline forms of (S,E)-4-(2-(3-(3-chloro-2-fluoro-6-(1H-tetrazol-1-yl)phenyl)acryloyl)-5-(4-methyl-2-oxopiperazin-1-yl)-1,2,3,4-tetrahydroisoquinoline-1-carboxamido)benzoic acid and its solvates thereof; processes for the production of such crystalline forms; pharmaceutical compositions comprising such crystalline forms; and methods of treating thromboembolic disorders with such crystalline forms or such pharmaceutical compositions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.